Noura M, Matsuo H, Yasuda T, Tsuzuki S, Kiyoi H, Hayakawa F
Oncogene. 2023; 43(6):447-456.
PMID: 38102337
DOI: 10.1038/s41388-023-02913-1.
Day R, Hickman J, Xu Z, Katerndahl C, Ferraro F, Ramakrishnan S
J Clin Invest. 2023; 134(4).
PMID: 38061017
PMC: 10866659.
DOI: 10.1172/JCI176311.
Rahmawati M, Stadler K, Lopez-Biladeau B, Hoisington T, Law N
Front Cell Dev Biol. 2023; 11:1284184.
PMID: 38020932
PMC: 10653448.
DOI: 10.3389/fcell.2023.1284184.
Malvi P, Chava S, Cai G, Hu K, Zhu L, Edwards Y
Cell Rep Med. 2023; 4(11):101285.
PMID: 37951219
PMC: 10694669.
DOI: 10.1016/j.xcrm.2023.101285.
Bogdanov K, Kudryavtseva E, Fomicheva Y, Churkina I, Lomaia E, Girshova L
Pathophysiology. 2023; 30(3):296-313.
PMID: 37606386
PMC: 10443239.
DOI: 10.3390/pathophysiology30030024.
Isoforms of the TAL1 transcription factor have different roles in hematopoiesis and cell growth.
Sharma A, Mistriel-Zerbib S, Najar R, Engal E, Bentata M, Taqatqa N
PLoS Biol. 2023; 21(6):e3002175.
PMID: 37379322
PMC: 10335695.
DOI: 10.1371/journal.pbio.3002175.
Inducible MLL-AF9 Expression Drives an AML Program during Human Pluripotent Stem Cell-Derived Hematopoietic Differentiation.
Heuts B, Arza-Apalategi S, Alkema S, Tijchon E, Jussen L, Bergevoet S
Cells. 2023; 12(8).
PMID: 37190104
PMC: 10136707.
DOI: 10.3390/cells12081195.
, a novel RUNX1 target gene, is down-regulated by RUNX1-ETO.
Matsumoto A, Yoshida T, Shima T, Yamasaki K, Tadagaki K, Kondo N
BBA Adv. 2023; 2:100047.
PMID: 37082605
PMC: 10074976.
DOI: 10.1016/j.bbadva.2022.100047.
The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy.
Setia Budi H, Younus L, Hadi Lafta M, Parveen S, Mohammad H, Al-Qaim Z
Front Oncol. 2023; 12:1067974.
PMID: 36793341
PMC: 9923359.
DOI: 10.3389/fonc.2022.1067974.
RNA-binding proteins of KHDRBS and IGF2BP families control the oncogenic activity of MLL-AF4.
Okuda H, Miyamoto R, Takahashi S, Kawamura T, Ichikawa J, Harada I
Nat Commun. 2022; 13(1):6688.
PMID: 36335100
PMC: 9637093.
DOI: 10.1038/s41467-022-34558-1.
A direct comparison between AML1-ETO and ETO2-GLIS2 leukemia fusion proteins reveals context-dependent binding and regulation of target genes and opposite functions in cell differentiation.
Zhang Y, Wang X, Xu C, Liu N, Zhang L, Zhang Y
Front Cell Dev Biol. 2022; 10:992714.
PMID: 36158200
PMC: 9490184.
DOI: 10.3389/fcell.2022.992714.
Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia.
Lim F, Chan A, Yokomori R, Huang X, Theardy M, Yeoh A
Haematologica. 2022; 108(2):367-381.
PMID: 36073513
PMC: 9890034.
DOI: 10.3324/haematol.2022.280761.
Arginine Methyltransferase PRMT7 Deregulates Expression of RUNX1 Target Genes in T-Cell Acute Lymphoblastic Leukemia.
Oksa L, Makinen A, Nikkila A, Hyvarinen N, Laukkanen S, Rokka A
Cancers (Basel). 2022; 14(9).
PMID: 35565298
PMC: 9101393.
DOI: 10.3390/cancers14092169.
Monoallelic Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.
Veiga D, Tremblay M, Gerby B, Herblot S, Haman A, Gendron P
Front Immunol. 2022; 13:867443.
PMID: 35401501
PMC: 8987207.
DOI: 10.3389/fimmu.2022.867443.
Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.
Passet M, Kim R, Gachet S, Sigaux F, Chaumeil J, Galland A
Blood. 2022; 139(24):3505-3518.
PMID: 35316324
PMC: 9203705.
DOI: 10.1182/blood.2021014723.
Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy.
Luo X, Ji X, Xie M, Zhang T, Wang Y, Sun M
Cancers (Basel). 2022; 14(5).
PMID: 35267473
PMC: 8909699.
DOI: 10.3390/cancers14051165.
UBC9 inhibits myeloid differentiation in collaboration with AML1-MTG8.
Fukuyama T, Kitamura T, Kozu T
Int J Hematol. 2022; 115(5):686-693.
PMID: 35152350
DOI: 10.1007/s12185-022-03303-1.
Tumor necrosis factor‑related apoptosis‑inducing ligand is a novel transcriptional target of runt‑related transcription factor 1.
Yoshida T, Yamasaki K, Tadagaki K, Kuwahara Y, Matsumoto A, Sofovic A
Int J Oncol. 2021; 60(1).
PMID: 34958111
PMC: 8727134.
DOI: 10.3892/ijo.2021.5296.
An updated account on molecular heterogeneity of acute leukemia.
Rahul E, Goel H, Chopra A, Ranjan A, Gupta A, Meena J
Am J Blood Res. 2021; 11(1):22-43.
PMID: 33796387
PMC: 8010602.
Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.
Takao S, Forbes L, Uni M, Cheng S, Pineda J, Tarumoto Y
Elife. 2021; 10.
PMID: 33527899
PMC: 7886351.
DOI: 10.7554/eLife.65905.